scholarly journals A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

2019 ◽  
Vol 25 (18) ◽  
pp. 5475-5484 ◽  
Author(s):  
Razelle Kurzrock ◽  
Douglas W. Ball ◽  
Marianna L. Zahurak ◽  
Barry D. Nelkin ◽  
Vivek Subbiah ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Phase I Trial ◽  
Kinase Inhibitor ◽  
Mek Inhibitor ◽  
Vegf Receptor ◽  
Advanced Solid Tumors ◽  
Differentiated Thyroid Cancers

P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S182
Author(s):  
Catherine Wheeler ◽  
Hironobu Minami ◽  
Hiromichi Ebi ◽  
Makoto Tahara ◽  
Yasutsuna Sasaki ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Receptor Tyrosine Kinase ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Vegf Receptor ◽  
Receptor Tyrosine Kinase Inhibitor

scholarly journals The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

2017 ◽  
Vol 116 (11) ◽  
pp. 1402-1407 ◽  
Author(s):  
Rachna T Shroff ◽  
Mark Yarchoan ◽  
Ashley O'Connor ◽  
Denise Gallagher ◽  
Marianna L Zahurak ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Mek Inhibitor ◽  
Vegf Receptor ◽  
Receptor Tyrosine Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document